AIM ImmunoTech (AIM) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($4.6 million vs $4.0 million), about 1.1 times the size, while Scilex is growing revenue faster (-46.5% vs -48.2%). Scilex converts more of its revenue into profit, with a net margin of -1236.4% versus -15861.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | SCLX |
|---|---|---|
| Share price | $0.1146 | $0.5658 |
| Market cap | $4.57M | $3.98M |
| 1-day change | -4.50% | -12.95% |
| YTD return | — | -92.55% |
| 1-year return | — | -95.96% |
| 5-year return | — | -99.74% |
| Forward P/E | — | 0.78 |
| EPS (TTM) | $-1.20 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $88.00K | $30.25M |
| Revenue growth (YoY) | -48.24% | -46.54% |
| Net income (latest FY) | $-13.96M | $-374.05M |
| Gross margin | — | 415.83% |
| Operating margin | -13254.55% | -1143.71% |
| Net margin | -15861.36% | -1236.42% |
| 52-week high | $1.82 | $14.34 |
| 52-week low | $0.1068 | $0.50 |
| Distance from 52-week high | -93.72% | -96.05% |
| Analyst consensus | none | — |
| Avg. price target upside | +3608.55% | — |
| Average volume | 4.40M | 56.11K |
| Shares outstanding | 39.92M | 7.03M |
| Employees | 19 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Scilex is more profitable, keeping -1236.4 cents of every revenue dollar as net income versus -15861.4 cents for AIM ImmunoTech.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
AIM vs SCLX FAQ
Which is bigger, AIM ImmunoTech or Scilex?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $4.57M compared with $3.98M for Scilex (SCLX).
Are AIM ImmunoTech and Scilex in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.